{"denoms":[{"counts":[{"groupId":"BG000","value":"45"}],"units":"Participants"}],"groups":[{"description":"Single arm.\n\nCarfilzomib: Subjects will receive the appropriate dose of carfilzomib (according to assigned cohort in phase 1 and at the determined MTD in phase 2) on days -3 and -2. Carfilzomib will be infused over 30 minutes. Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.\n\nMelphalan: Subjects will receive 200 mg/m2 of intravenous melphalan on Day -2. Administered as an intravenous push or a fast infusion according to institutional standard operating procedure (SOP). Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.","id":"BG000","title":"Carfilzomib + High Dose Melphalan"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"41","upperLimit":"69","value":"58"}]}]}],"description":"Time in years from birth to enrollment","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"20"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}]}],"title":"Non-Hispanic Whites"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}]}],"title":"Non-Hispanic Blacks"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Other"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Patients with relapsed multiple myeloma, candidates for autologous hematopoietic cell transplantation"}